1142 Comparative overall survival with treatment sequences for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies

2014 ◽  
Vol 13 (1) ◽  
pp. e1142
Author(s):  
D.Y. Heng ◽  
J. Signorovitch ◽  
E. Swallow ◽  
N. Li ◽  
Y. Zhong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
Observational Studies ◽  
Meta Analysis ◽  
Treatment Sequences

scholarly journals Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis

BMJ Open ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. e024691 ◽  
Author(s):  
Charlotta Karner ◽  
Kayleigh Kew ◽  
Victoria Wakefield ◽  
Natalie Masento ◽  
Steven J Edwards
Keyword(s):  
Systematic Review ◽  
Renal Cell Carcinoma ◽  
Sensitivity Analysis ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Observational Studies ◽  
Meta Analysis ◽  
Targeted Treatment

ObjectiveTo compare the effectiveness and safety of treatments for advanced or metastatic renal cell carcinoma (amRCC) after treatment with vascular endothelial growth factor (VEGF)-targeted treatment.DesignSystematic review and network meta-analysis of randomised controlled trials (RCTs) and comparative observational studies. MEDLINE, EMBASE and Cochrane Library were searched up to January 2018.ParticipantsPeople with amRCC requiring treatment after VEGF-targeted treatment.InterventionsAxitinib, cabozantinib, everolimus, lenvatinib with everolimus, nivolumab, sorafenib and best supportive care (BSC).OutcomesPrimary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes were objective response rate (ORR), adverse events, and health-related quality of life (HRQoL).ResultsTwelve studies were included (n=5144): five RCTs and seven observational studies. Lenvatinib with everolimus significantly increased OS and PFS over everolimus (HR 0.61, 95% Credible Interval [95%CrI]: 0.36 to 0.96 and 0.47, 95%CrI: 0.26 to 0.77, respectively) as did cabozantinib (HR 0.66, 95%CrI: 0.53 to 0.82 and 0.51, 95%CrI: 0.41 to 0.63, respectively). This remained the case when observational evidence was included. Nivolumab also significantly improved OS versus everolimus (HR 0.74, 95%CrI: 0.57 to 0.93). OS sensitivity analysis, including observational studies, indicates everolimus being more effective than axitinib and sorafenib. However, inconsistency was identified in the OS sensitivity analysis. PFS sensitivity analysis suggests axitinib is more effective than everolimus, which may be more effective than sorafenib. The results for ORR supported the OS and PFS analyses. Nivolumab is associated with fewer grade 3 or grade 4 adverse events than lenvatinib with everolimus or cabozantinib. HRQoL could not be analysed due to differences in tools used.ConclusionsLenvatinib with everolimus, cabozantinib and nivolumab are effective in prolonging the survival for people with amRCC subsequent to VEGF-targeted treatment, but there is considerable uncertainty about how they compare to each other and how much better they are than axitinib and sorafenib.PROSPERO registrationnumberCRD42017071540.

scholarly journals Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data

2019 ◽  
Vol 14 (4) ◽  
pp. 405-416 ◽  
Author(s):  
Michael Moran ◽  
Dana Nickens ◽  
Katherine Adcock ◽  
Meg Bennetts ◽  
Arial Desscan ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document